Caricamento azienda
Just reported
From Protagonist Therapeutics's results release of 5 novembre 2026; its quarterly report has since been filed.
Actual
274,4M USD
+29% q/q
Guided
—
No guide given
Actual
3,07 USD
+34% q/q
Guided
—
No guide given
Actual
218,3M USD
+38% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Protagonist Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now AIcotyde (icotrokinra)
An oral peptide medicine that blocks the interleukin-23 receptor, a part of the immune system involved in plaque psoriasis. It is approved in the United States for plaque psoriasis and is licensed to Janssen.
Rusfertide
An injected medicine that imitates hepcidin, a natural hormone that regulates iron. It is being reviewed by U.S. regulators as a treatment for polycythemia vera, a rare disease in which the body makes too many red blood cells.
PN-881
An oral peptide medicine that blocks interleukin-17, an immune-system signal involved in inflammatory skin diseases. It is being studied as a possible treatment for psoriasis and related conditions.
PN-477
A peptide designed to activate the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors. It is being developed for obesity in oral and injectable forms.
PN-458
A peptide designed to activate the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. It is being developed for obesity in oral and injectable forms.
PN-8047
An oral small-molecule medicine designed to imitate hepcidin and regulate iron. It is being developed as a possible treatment for polycythemia vera.
Protagonist discovers and develops medicines, including peptide drugs made from short chains of amino acids. It licenses Icotyde to Janssen, part of Johnson & Johnson, which is responsible for its development and commercialization; Protagonist can receive milestone payments and royalties on sales. Takeda has the worldwide rights to develop and commercialize rusfertide, while Protagonist also advances medicines of its own for immune diseases, blood disorders and obesity.
Costruito dai documenti depositati da Protagonist Therapeutics, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
Protagonist licenses medicines for psoriasis and a rare blood disorder to drug companies, which pay milestone fees and royalties, while developing treatments for obesity.
Grade A+
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 27 dello storico dei voti di Protagonist Therapeutics, Inc.. Gli altri 25 risalgono fino a marzo 2019.
